In vivo virulence of Candida albicans isolates causing mucosal infections in people infected with the human immunodeficiency virus

被引:28
作者
Taylor, BN
Fichtenbaum, C
Saavedra, M
Slavinsky, J
Swoboda, R
Wozniak, K
Arribas, A
Powderly, W
Fidel, PL
机构
[1] Louisiana State Univ, Hlth Sci Ctr, Dept Microbiol Immunol & Parasitol, New Orleans, LA 70112 USA
[2] Washington Univ, Sch Med, Dept Med, Div Infect Dis, St Louis, MO 63110 USA
关键词
D O I
10.1086/315768
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mucosal candidiasis is common in human immunodeficiency virus (HIV) infection. Susceptibility to such infections may be attributed to reduced host defense mechanisms and/or virulence of the organism, In the present study, we compared the virulence of mucosal Candida albicans isolates from HIV-infected people, with and without fluconazole-refractory infection, in established murine models of systemic and vaginal candidiasis, Compared with the mortality rate (similar to 70%) after intravenous challenge with 2 virulent reference isolates, challenge with most clinical isolates (66%-77%) resulted in prolonged survival. In contrast, fungal burden induced by intravaginal challenge of nearly all (97%) isolates was similar to that of the virulent controls. There were no differences in in vitro growth rates for any of the isolates, and there was no association between reduced mortality and clinical failure to fluconazole, in vitro antifungal susceptibility, site of infection, or other host factors. These results suggest that virulence of C, albicans is tissue specific and is not a factor in the development of fluconazole-refractory infections in advanced HIV disease.
引用
收藏
页码:955 / 959
页数:5
相关论文
共 15 条
[1]   In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors [J].
Cassone, A ;
De Bernardis, F ;
Torosantucci, A ;
Tacconelli, E ;
Tumbarello, M ;
Cauda, R .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :448-453
[2]   PUTATIVE VIRULENCE FACTORS OF CANDIDA-ALBICANS [J].
CUTLER, JE .
ANNUAL REVIEW OF MICROBIOLOGY, 1991, 45 :187-218
[3]   Refractory mucosal candidiasis in patients with human immunodeficiency virus infection [J].
Fichtenbaum, CJ ;
Powderly, WG .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (03) :556-565
[4]   Refractory mucosal candidiasis in advanced human immunodeficiency virus infection [J].
Fichtenbaum, CJ ;
Koletar, S ;
Yiannoutsos, C ;
Holland, F ;
Pottage, J ;
Cohn, SE ;
Walawander, A ;
Frame, P ;
Feinberg, J ;
Saag, M ;
Van der Horst, C ;
Powderly, WG .
CLINICAL INFECTIOUS DISEASES, 2000, 30 (05) :749-756
[5]   MICE IMMUNIZED BY PRIMARY VAGINAL CANDIDA-ALBICANS INFECTION DEVELOP ACQUIRED VAGINAL MUCOSAL IMMUNITY [J].
FIDEL, PL ;
LYNCH, ME ;
CONAWAY, DH ;
TAIT, L ;
SOBEL, JD .
INFECTION AND IMMUNITY, 1995, 63 (02) :547-553
[6]   CANDIDA-SPECIFIC TH1-TYPE RESPONSIVENESS IN MICE WITH EXPERIMENTAL VAGINAL CANDIDIASIS [J].
FIDEL, PL ;
LYNCH, ME ;
SOBEL, JD .
INFECTION AND IMMUNITY, 1993, 61 (10) :4202-4207
[7]  
Fidel PL, 1999, MEDICAL IMPORTANCE OF THE NORMAL MICROFLORA, P441
[8]   Efficacy of D0870 treatment of experimental Candida vaginitis [J].
Fidel, PL ;
Cutright, JL ;
Sobel, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1455-1459
[9]   HORMONAL FACTORS IN VAGINAL CANDIDIASIS IN RATS [J].
KINSMAN, OS ;
COLLARD, AE .
INFECTION AND IMMUNITY, 1986, 53 (03) :498-504
[10]   ORAL CANDIDIASIS IN HIGH-RISK PATIENTS AS THE INITIAL MANIFESTATION OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME [J].
KLEIN, RS ;
HARRIS, CA ;
SMALL, CB ;
MOLL, B ;
LESSER, M ;
FRIEDLAND, GH .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (06) :354-358